## VTRS: Viatris Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.8% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($10.15)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. |Viatris, Inc. Trade Ideas — SIX:VTRS.USD**
- Source: TradingView | 20251201T085151 | Bullish | Relevance: 99%
-  |This compilation of trade ideas for Viatris, Inc. (VTRS.USD SIX Swiss Exchange) presents various analyses ranging from long-term dividend plays and Fibonacci analysis for entry points to short-term trading signals and comparative analyses with other pharmaceutical stocks like MRK. Analysts provide specific price targets, stop losses, and entry points, utilizing technical indicators like SMA, ATR Keltner Channel, and Elliot Wave theory, while also discussing sentiment and fundamental considerations.

**2. Cash per share of Viatris, Inc. – SIX:VTRS.USD**
- Source: TradingView | 20251130T070703 | Neutral | Relevance: 99%
- This page provides financial data, specifically "Cash per share," for Viatris, Inc. (SIX:VTRS.USD). It indicates that the market was closed and no trades were made during the observed period. The content emphasizes current financial metrics for Viatris, Inc. accessible through TradingView.

**3. Viatris Inc. Reports Steady Q3 2025 Performance**
- Source: MSN | 20251201T085151 | Somewhat-Bullish | Relevance: 99%
- Viatris Inc. (VTRS) announced steady performance for Q3 2025, with revenues largely meeting expectations despite a slight year-over-year decrease. The company reaffirmed its full-year 2025 guidance and highlighted progress in its strategic initiatives, including deleveraging and portfolio optimization.

**4. Levi & Korsinsky Notifies Viatris Inc. (VTRS) Shareholders of Class Action Lawsuit and June 3, 2025 Deadline**
- Source: The National Law Review | 20251130T093648 | Neutral | Relevance: 98%
- Levi & Korsinsky LLP has announced a class action lawsuit against Viatris Inc. (NASDAQ:VTRS) on behalf of shareholders who suffered losses due to alleged securities fraud between August 8, 2024, and February 26, 2025. The lawsuit claims Viatris misrepresented the impact of an FDA warning letter on its Indore, India facility, leading to a significant stock price decline on February 27, 2025. Shareholders have until June 3, 2025, to join the lawsuit.

**5. Net income before discontinued operations of Viatris, Inc. – SIX:VTRS**
- Source: TradingView | 20251130T070703 | Neutral | Relevance: 98%
- This page displays financial information for Viatris, Inc. (SIX:VTRS), specifically focusing on net income before discontinued operations. It provides a quick overview of financial data for the company's stock on the SIX Swiss Exchange.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $15 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-3.3%)
- Price (T.Rowe) Assoc: 7.3% (+6.7%)
- Blackrock Inc.: 7.1% (-1.1%)
- Davis Selected Advis: 6.0% (+4.5%)
- State Street Corpora: 4.8% (+0.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 4.3x attractive for 7% earnings growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $13.4B |
| Beta | 0.83 |
| 52W Range | $6.85 - $13.13 |
| Short Interest | 2.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 4.3 |
| Current P/E | 4.6 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 3.8pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.77% (CS: 57) | Neutral |
| RSI_14 | 55.7 | Neutral |
| MACD Histogram | -0.01 | Bearish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 1.042x | Above |
| vs SMA200 | 1.131x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $10.71
- **Stop Loss:** $10.15 (5.2% risk)
- **Target:** $11.27 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1785
- **Position Value:** $19,117.35
- **Portfolio %:** 19.12%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-26 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.62 | $0.67 | +8.5% |
| 2025Q2 | $0.56 | $0.62 | +11.6% |
| 2025Q1 | $0.49 | $0.50 | +1.6% |
| 2024Q4 | $0.57 | $0.54 | -5.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*